
Module: CNS

Subject: Pharmacology

Lecture: MBBS







Antidepressant Drugs-1



Dr Biswadeep Das Assoc Prof(Pharmacology)

Department of Pharmacology/AIIMS Rishikesh biswadeepdas@hotmail.com

Mental Depression... What is it?



What is Mental Depression?-Mood Disorder

- Unipolar Depression (Major Depression)
 - Strong and enduring feelings of sadness, hopelessness, worthlessness, and inability to experience pleasure.
 - Relatively common.

Pleasure seeking = Hedonistic Inability to experience pleasure = Anhedonia

Disorders of Mood (Affective Disorders)


- Depression (unipolar depression)
- Mania
- Manic-depression (bipolar depression)

- Reactive depression (75%)
- Endogenous depression (25%)

What are the possible mechanisms of depression?


- Depression is associated with insufficient central release of NE and 5-HT
- Led to development of the Biogenic Amine Hypothesis

Antidepressant Drugs-Classification



■ Tricyclic Agents


☐ Imipramine/Desipramine/ Clomipramine/ Amitriptyline/Nortriptyline/ Protriptyline/Doxepin/ Nordoxepin



Sertraline

Source: Katzung BG, Masters SB, Trevor AJ: Basic & Clinical Pharmacology, 12th edition: www.accessmedicine.com

Antidepressant Drugs-Classification (contd.)



Source: Katzung BG, Masters SB, Trevor AJ: Basic & Clinical Pharmacology, 12th edition: www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.


$$0 \longrightarrow N - CH_2 - CH_2 - CH_2 - N \longrightarrow CI$$

Trazodone

- Heterocyclic Agents
 - □Unicyclic
 - Bupropion
 - □Tetracyclic
 - Amoxapine(N-desmethyl loxapine)/Maprotilene/ Mirtazapine
- 5-HT₂ Antagonists
 - Nefazodone/Trazodone

Antidepressant Drugs-Classification (contd.)

- Mono-Amine-Oxidase-A Isozyme Inhibitors (MAO-Al's)
 - ■Hydrazine group
 - Isocarboxazid/Phenelzine
 - ■Nonhydrazine group




Phenelzine

Tranylcypromine

Nialamide/Tranylcypromine/Clorgyline/Pargyline/ Moclobemide/Brofaromine/Cimoxatone/Toloxatone

Selective Serotonin Reuptake Inhibitors (SSRI's)



www.accessmedicine.com

Source: Katzung BG, Masters SB, Trevor AJ: Basic & Clinical Pharmacology, 12th edition:

- Selective Serotonin Reuptake Inhibitors (SSŘľs)
 - □Citalopram/ Escitalopram/ Fluoxetine/ Paroxetine/ Sertraline/ **Fluvoxamine**

Serotonin NE Reuptake Inhibitors (SNRI's)


 $R = CH_3$: Venlafaxine

R = H: Desvenlafaxine

Duloxetine


- Serotonin Norepinephrine Reuptake Inhibitors (SNRI's)
 - □Duloxetine
 - □Venlafaxine
 - □Desvenlafaxine

Postulated Mode of Action of Tricyclic Antidepressant Drugs




■ TCA's \rightarrow \downarrow NE/ \downarrow 5 -HT reuptake (↓ NET/ ↓ SERT) → **†monoaminergic** neurotransmission →Antidepressant action

Postulated Mode of Action of MAO-A Inhibitor Drugs



■ MAO-Al's \rightarrow \downarrow MAO-A isozyme → ↓ monoamine metabolism→ **†monoaminergic** neurotransmission →Antidepressant action

SSRI's-Mechanism of Action



■ SSRI's → selective ↓5-HT reuptake $(\downarrow SERT) \rightarrow$ **†monoaminergic** (serotonergic) neurotransmission →Antidepressant action

Tricyclic Antidepressants(TCA's)-Pharmacological Actions

- CNS Actions
 - Mood elevation in depressed patients
 - □ Latency period: 2-4 weeks
 - □ Can cause EPS/Ataxia/Seizures/Coma
- CVS Actions
 - □ Orthostatic hypotension → ↑ HR
- ANS Actions
 - ■Anticholinergic effects
 - Most potent anticholinergic action(Amitriptyline)

Tricyclic Antidepressants(TCA's)-Pharmacokinetics

- Absorption
 - ■Well absorbed orally
- Distribution
 - $\Box \uparrow Lipophilic \rightarrow \uparrow V_d \rightarrow \uparrow T(1/2)$
- Metabolism & Excretion
 - □ Hepatic microsomal N-demethylation/ oxidation/glucuronidation→Renal Elimination

Tricyclic Antidepressants(TCA's)-Therapeutic Uses

- Severe endogenous depression (TCA's drug of choice)
- Nocturnal enuresis(Imipramine)
- Panic Disorder(Imipramine)
- Obsessive-Compulsive Disorders(Clomipramine)
- Chronic Neuropathic Pain(e.g., Trigeminal Neuralgia/Diabetic Neuropathy/Tabetic Neuropathy)
- Others(Eating Disorders(Bulimia)/Narcolepsy/ School Phobia/ADHD)

Tricyclic Antidepressants(TCA's)-Adverse Effects

- Excessive sedation/Lassitude/Fatigue/Confusion
- Sympathomimetic effects(Tachycardia/Agitation/Sweating/ Insomnia)
- Anticholinergic('Atropine-like") effects
- Orthostatic hypotension/ECG abnormalities/Cardiomyopathies
- Tremor/Paresthesias/EPS

Tricyclic Antidepressants(TCA's)-Adverse Effects


- Weight gain
- Overdosage(extremely hazardous): Remember 3C's
 - □ Agitation/Delirium/Neuromuscular irritability/Convulsions/Coma
 - □ Respiratory depression/Circulatory collapse
 - □ Hyperpyrexia
 - □ Cardiotoxicity(Cardiac conduction defects/Severe arrhythmias)

Module: CNS

Subject: Pharmacology

Lecture: MBBS







Antidepressant Drugs-2



Dr Biswadeep Das Assoc Prof(Pharmacology)

Department of Pharmacology/AIIMS Rishikesh biswadeepdas@hotmail.com


MAO-AI's-Pharmacological Actions

- CNS Actions
 - ■Mood elevation
 - □Latency period: 2-3 weeks
 - □Tranylcypromine → Amphetaminelike → causes NE release in CNS → antidepressant action(48 h)
 - □MAOI's→↓REM sleep/↓Narcolepsy

MAO-AI's-Pharmacological Actions (contd.)

- CVS Actions
 - □Postural hypotension
 - □Beer/Cheese/Chicken Liver→↑Tyramine
 content/↓Tyramine metabolism→
 ↑↑catecholamine release(nerve
 terminals) →Hypertensive Crisis(Cheese
 Reaction)

MAOI Interaction with Tyramine



- Tyramine is normally metabolized by MAO in gut and liver
- If unmetabolized, tyramine enters sympathetic nerve terminals where it displaces NE from vesicles into cytosol

MAOI Interaction with Tyramine ('Cheese Reaction')(contd.) CH2CH2NH2 HO Tyramine OH Noradrenaline

- Because MAO in the nerve terminals is inhibited there is a massive 'non-physiological' release of NE from sympathetic nerve terminals which can lead to fatal hemorrhage
- Patients prescribed an MAOI are warned not to eat/ drink certain substances (substances that contain tyramine etc.) e.g. beer, wine, cheese, marmite

MAO-AI's-Pharmacological Actions (contd.)

- Hepatic Actions
 - □Cause hepatotoxicity
 - □Interference with drug detoxification

MAO-AI's-Pharmacokinetics

- MAO inhibitors are taken orally
- They are 'hit & run' drugs i.e., their effects greatly outlast their detectable presence in the body because they inhibit the enzyme irreversibly & termination of effect is dependent on synthesis of fresh enzyme(which takes weeks)
- The hydrazine group is acetylated(like INH) & the population is divided into slow & fast acetylators

MAO-AI's-Therapeutic Uses

- Atypical Depression
 - □Hyperanxiety/Hyperphagia/Hypersomnolence
- Panic Disorder


MAO-AI's-Adverse Effects & Drug Interactions

- Adverse Effects
 - □ Headache/Drowsiness/Dry mouth/Weight gain/ Orthostatic hypotension/Impotence/Cheese Reaction
- Drug Interactions
 - ■MAOI's + SSRI's → Serotonin Syndrome(lethal)
 - □TCA's + CNS Depressants → ↑↑ CNS depression
 - □TCA's + MAOI's→ Hyperpyrexia/Convulsions/ Coma

Selective Serotonin Reuptake Inhibitors (SSRI's)



Selective Serotonin Reuptake Inhibitors (SSRI's)



Citalopram

- Structurally distinct from the tricyclic molecules
- Have fewer adverse effects than the tricyclics and have become popular

Source: Katzung BG: Basic & Clinical Pharmacology, 10th Edition: http://www.accessmedicine.com

Selective Serotonin Reuptake Inhibitors(SSRI's)-Pharmacokinetics

- Absorption
 - ■Well-absorbed orally
- Distribution
- Metabolism
 - □Fluoxetine → Norfluoxetine
- Excretion
 - □Renal elimination
 - □Elimination T(1/2)= 1-3 d(Fluoxetine)/ 7-15 d(Norfluoxetine)

Selective Serotonin Reuptake Inhibitors(SSRI's)-Therapeutic Uses

- Endogenous Depression
- Obsessive-Compulsive Disorders
 - □Fluoxetine/Clomipramine
- Panic Disorder

Case 7-Obsessive Compulsive Disorder(OCD)

- A 33-year-old woman presents with a 7-year history of hand washing for 2-6 hours a day, as well as urges to check doors and stoves extensively before leaving her home.
- Her life is restricted, and her family members are upset about her behavior.
- How should she be evaluated and treated?

[Jenike MA. Obsessive compulsive disorder. New Engl J Med 2004; 350: 259-265.]

Case 7-Obsessive Compulsive Disorder(OCD)

Table 1. DSM-IV Diagnostic Criteria for OCD.*

Either obsessions or compulsions

Obsessions are defined by the following:

Recurrent and persistent thoughts, impulses, or images that are experienced, at some time during the disturbance, as intrusive and inappropriate and that cause marked anxiety or distress

Thoughts, impulses, or images that are not simply excessive worries about real-life problems

The effort by the affected person to ignore or suppress such thoughts, impulses, or images, or to neutralize them with some other thought or action

Recognition by the affected person that the obsessional thoughts, impulses, or images are a product of his or her own mind rather than imposed from without

Compulsions are defined by the following:

Repetitive activities (e.g., hand washing, ordering, checking) or mental acts (e.g., praying, counting, repeating words silently) that the person feels driven to perform in response to an obsession or according to rules that must be applied rigidly

Behavior or mental acts aimed at preventing or reducing distress or preventing some dreaded event or situation but either clearly excessive or not connected in a realistic way with what they are designed to neutralize or prevent

Recognition, by the affected person (unless he or she is a child), at some point during the course of the disorder, that the obsessions or compulsions are excessive or unreasonable

Obsessions or compulsions that cause marked distress, are time consuming (take more than 1 hr/day), or interfere substantially with the person's normal routine, occupational or academic functioning, or usual social activities or relationships

Content of the obsessions or compulsions not restricted to any other Axis I disorder, such as an obsession with food in the context of an eating disorder, that is present

Disturbance not due to the direct physiological effects of a substance or a general medical condition

Specified as OCD with poor insight if, for most of the time during the current episode, the person does not recognize that the obsessions and compulsions are excessive or unreasonable

Behavioural Therapy Cognitive Therapy Medications

Treatment	Initial Daily Dose	Target Daily Dose	Common Side Effects
	,		
Selective serotonin-reuptake inhibitors†			Anxiety, decreased libido, sexual dysfunction, diarrhea, sedation, headache, insomnia, dizziness, nausea
Fluoxetine (Prozac)	20	80	
Fluvoxamine (Luvox)	50	300	
Sertraline (Zoloft)	50	200	
Paroxetine (Paxil)	20	60	
Citalopram (Celexa)	20	60	
Escitalopram (Lexapro)	10	Unknown	
Clomipramine (Anafranil, tricyclic antidepressant)	25–50	250	Dizziness, sedation, dry mouth, weight gain, sexual dysfunction
Venlafaxine (Effexor)	75	375	Accommodation disorder, blurred vision, headache, ser ual dysfunction, paresthesias, nausea, weight loss, withdrawal syndrome (dizziness, nausea, weakness

^{*} OCD denotes obsessive-compulsive disorder.

Jenike MA. Obsessive compulsive disorder. New Engl J Med 2004; 350: 259-265.

^{*} DSM-IV denotes Diagnostic and Statistical Manual of Mental Disorders, fourth edition, and OCD obsessive—compulsive disorder.

[†] All selective serotonin-reuptake inhibitors except escitalopram have been formally studied in patients with OCD. Side-effect profiles may vary among these agents; an alternative agent in this class should be tried if one agent proves to be ineffective or is associated with substantial side effects.

Selective Serotonin Reuptake Inhibitors(SSRI's)-Adverse Effects

- "Less serious"
- Anorexia/Nausea
- Hypomania/Mania/Nervousness/Headache/Insomnia/ Dizziness/EPS
- QT Prolongation(Citalopram)
- Hyponatremia(5-HT 5-HT_{1C} & 5-HT₂ Receptors ADH release)
 - ☐ Citalopram/Fluoxetine/Fluvoxamine/Paroxetine/Sertraline
- Sexual dysfunction
- Serotonin syndrome

[Ray S, et al. The use of antidepressant medication in pregnancy. Best Practice & Research Clinical Obstetrics & Gynecology 2014; 28: 71-83.]

[Isbister GK, et al. Serotonin toxicity: a practical approach to diagnosis and treatment. Medical Journal of Australia 2007; 187: 361-5.] [Jacob S & Spinler SA. Hyponatremia associated with selective serotonin reuptake inhibitors in older adults. Ann Pharmacother 2006; 40: 1618-22.]

- Fluvoxamine
 - \Box (\downarrow CYP 1A2 & 2C19)
 - □(↓CYP 3A4 & 2C9)

Fluoxetine/Paroxetine

 \Box (\downarrow CYP 2D6)

SSRI	Significant PK Interactions(↑ Plasma Levels & Potential Adverse Effects)
Sertraline	Clozapine Unlikely to cause other clinically significant pharmacokinetic drug interactions


SSRI	Significant PK Interactions(↑ Plasma Levels & Potential Adverse Effects)		
Citalopram/ Escitalopram	Unlikely to cause clinically significant pharmacokinetic drug interactions but contra-indicated with other drugs which can prolong QT interval		


SSRI	Significant PD Interactions			
Sertraline/	Potential Serotonin Syndrome when combined with:			
Citalopram/	Other Antidepressants(5-HT-enhancing)			
Escitalopram	Buspirone/Fentanyl/Linezolid/Lithium/Ondansetron/St. John's Wort/Tramadol			
	Increased risk of bleeding (particularly upper GI bleed) with: NSAIDs/Warfarin and other anticoagulants/Antiplatelets			
	Other PD interactions to consider: Other drugs which can also cause sexual dysfunction(antipsychotics), GI effects(acetylcholinesterase inhibitors) or hyponatremia (thiazide diuretics)			

- Potentially life-threatening condition caused by excessive serotonergic activity in CNS
- Characterized by:
 - Mental status changes
 - □ Autonomic instability, &
 - □ Neuromuscular hyperactivity
- Most cases reported in patients:
 - □ Using multiple serotonergic drugs or
 - □ Who have had considerable exposure to a single serotoninaugmenting drug
- Diagnostic Criteria: Dursun/Hunter/Radomski/Sternbach

- Diagnosis is made using the Hunter Serotonin Toxicity
 Criteria
- Require the presence of ONE of the following classical features or groups of features:
 - □ Spontaneous clonus
 - Inducible clonus + [agitation OR diaphoresis]
 - Ocular clonus + [agitation OR diaphoresis]
 - □ Tremor + hyperreflexia
 - ☐ Hypertonia + Temperature > 100.4°F(38°C) +[ocular clonus OR inducible clonus]

[Ables AZ, Nagubilli R. Prevention, recognition and management of serotonin syndrome. Am Fam Physician 2010; 81(9): 1139-42.]





1 Drugs that have been associated with serotonin toxicity

Serotonin reuptake inhibitors

- Selective serotonin reuptake inhibitors: fluoxetine, fluvoxamine, paroxetine, citalopram, sertraline, escitalopram
- Other antidepressants: venlafaxine, clomipramine, imipramine
- Opioid analgesics: pethidine, tramadol, fentanyl, dextromethorphan
- St John's wort

Monoamine oxidase inhibitors


- Irreversible monoamine oxidase A inhibitors: phenelzine, tranylcypromine
- Reversible monoamine oxidase A inhibitors: moclobemide
- Others: linezolid

Serotonin-releasing agents

- Fenfluramine
- Amphetamines
- Methylenedioxymethamphetamine (MDMA; ecstasy)

Miscellaneous

- Lithium
- Tryptophan






Table 2

Combinations That May Result in Serotonin Syndrome

All SSRIs in combination

Venlafaxine & lithium

Venlafaxine & moclobemide

Venlafaxine & fluoxetine

Venlafaxine & mirtazapine

Fluoxetine & sertraline

Fluoxetine & tramadol

Trazodone & buspirone

Clomipramine & MAOI

Clomipramine & trazodone

Clomipramine & moclobemide

Dextromethorphan & paroxetine

Dextromethorphan & moclobemide

Linezolid & citalopram


SSRI & St. John's wort

SSRI & MAOI

Meperidine & MAOI

SSRI: selective serotonin reuptake inhibitor; MAOI: monoamine oxidase inhibitor.

Source: References 2, 6, 9.








Table 4

Clinical Presentation of Serotonin Syndrome and Differential Diagnosis

Clinical Presentation	Serotonin Syndrome	NMS	Anticholiner- gic Delirium
Tachycardia	+	+	+
Hypertension	+	+	+
Muscle rigidity	+	+	_
Hyperthermia >41.1°(C +	+	-
Hyperreflexia	+	-	_
Myoclonus	+	-	-
Shivering	+	-	_
Acute onset	_	_	+
Restlessness, confusion, agitation	+	-	+
Bowel sound	+	-	-

NMS: neuroleptic malignant syndrome; +: present; -: not present. Source: Reference 2.





- Most cases of SS are mild
- Treated by
 - Withdrawal of the offending agent +
 - □ Supportive care
- Benzodiazepines used to treat agitation + tremor
- Cyproheptadine used as an antidote
- Patients with moderate or severe cases of SS require hospitalization
- Critically ill patients may require:
 - Neuromuscular paralysis
 - □ Sedation, &
 - Intubation

Serotonin NE Reuptake Inhibitors(SNRI's)


Duloxetine

R = CH₃: Venlafaxine

R = H : Desvenlafaxine

- Bind to transporters for both serotonin and NE(NET + SERT)
- Enhance actions of both neurotransmitters
- SNRIs differ from the TCAs in lacking significant blocking effects on peripheral receptors including
 - Histamine(H₁)/Muscarinic/
 α-adrenergic receptors

Heterocyclics



Source: Katzung BG, Masters SB, Trevor AJ: Basic & Clinical Pharmacology, 12th edition: www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved


Bupropion

- ☐ Mechanism of antidepressant action unknown
- □ Drug has no effect on 5-HT or NE receptors nor on amine transporters

Mirtazapine

- Increases amine release from nerve endings by antagonism of presynaptic α₂ adrenoceptors involved in feedback inhibition
- □ Is also an antagonist at serotonin
 5-HT₂ receptors

Heterocyclics



Source: Katzung BG, Masters SB, Trevor AJ: Basic & Clinical Pharmacology, 12th edition: www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

- Amoxapine/Maprotiline
 - □ Are potent NET inhibitors + less potent SERT inhibitors
 - ■Both possess anticholinergic properties

5-HT₂ Antagonists

CH₃CH₂ N N-CH₂-CH₂-CH₂-N N-CH₂-CH₂-CH₂-N Nefazodone

$$\begin{array}{c|c}
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\
 & & \\$$

Trazodone

■ 5-HT₂ Antagonists

- Major antidepressant actions result from block of the 5-HT _{2A} receptor
- □ G-protein—coupled receptor located in several CNS regions including the neocortex
- Antagonism of this receptor is equated with both the antianxiety + antidepressant actions of these drugs